Uncategorized
SemaThera Board Names Garth Cumberlidge as President & CEO
MONTREAL--(BUSINESS WIRE)--#amorchem--SemaThera Inc., announces today that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retinopathies. Its lead compound, ST-102, is a bispecific recombinant protein trap, binding both VEGF and SEMA3A. “AmorChem is proud to welcome Garth Cumberlidge to the